From research to clinical: what does the path to FDA approval actually look like?

The FDA clinical trial process: Phase 1 (safety, 20-80 people, 1-2 years), Phase 2 (efficacy signals and dose-finding, 100-300 people, 2-3 years), Phase 3 (large efficacy trials, 1,000+ people, 3-5 years), then NDA submission and review (1-2 years). For psilocybin: COMPASS Pathways has completed Phase 2 and Phase 3 for treatment-resistant depression. Phase 3 results were positive. NDA expected 2025-2026. FDA review of psychedelic NDAs has been complicated by the MDMA experience — the FDA rejected MAPS's NDA for MDMA-PTSD in 2024 on process concerns, not efficacy data. This has created uncertainty in the timeline for psilocybin.

Breakthrough Therapy Designation: psilocybin received Breakthrough Therapy Designation from FDA for treatment-resistant depression (COMPASS) and major depressive disorder (Usona). This status accelerates review and provides more FDA guidance during development — it doesn't guarantee approval but does meaningfully compress the timeline. The designation reflects FDA's acknowledgment that existing therapies are inadequate and psilocybin shows substantial improvement over them.

Realistic timeline: FDA approval for psilocybin for treatment-resistant depression is possible in the 2026-2028 range if COMPASS's NDA is well-received. Broader indications (MDD, alcohol use disorder) would require additional approval processes. Even post-approval, scheduling and insurance coverage would take additional time. Widespread clinical availability is probably a 3-5 year horizon from FDA approval, given the need to train therapists and build infrastructure. Oregon and Colorado will continue to be the primary legal access points in the interim.